ストックスクリーナーアプリを入手
16.75
15.37%
2.231
プレマーケット:
17.16
0.409
+2.44%
前日終値:
$14.52
開ける：
$14.52
24時間の取引高:
1.77M
Relative Volume:
1.43
時価総額：
$1.39B
収益：
$46.02M
当期純損益:
$-70.80M
株価収益率:
-9.2038
EPS:
-1.82
ネットキャッシュフロー:
$-1.61M
1週間 パフォーマンス:
+13.26%
1か月 パフォーマンス:
+35.20%
6か月 パフォーマンス:
+104.28%
1年 パフォーマンス:
+97.30%
1日の値動き範囲:
$14.40
$17.00
1週間の範囲:
$13.61
$17.00
52週間の値動き範囲:
$3.91
$17.00
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
名前
Eyepoint Pharmaceuticals Inc
セクター
電話
617-926-5000
住所
480 PLEASANT STREET, WATERTOWN, MA
EYPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
16.75 | 1.20B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-07 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-28 | 開始されました | Jefferies | Buy |
| 2024-01-22 | 開始されました | JP Morgan | Overweight |
| 2023-11-02 | 開始されました | Mizuho | Buy |
| 2023-04-21 | 開始されました | Robert W. Baird | Outperform |
| 2022-07-07 | 開始されました | Chardan Capital Markets | Buy |
| 2021-03-01 | 開始されました | Cowen | Outperform |
| 2021-01-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-04-06 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 再開されました | Laidlaw | Buy |
| 2019-09-12 | 開始されました | Guggenheim | Buy |
すべてを表示
Eyepoint Pharmaceuticals Inc (EYPT) 最新ニュース
Will EyePoint Pharmaceuticals Inc. stock outperform value stocksQuarterly Portfolio Review & AI Powered Trade Plan Recommendations - Newser
How EyePoint Pharmaceuticals Inc. (PV3B) stock responds to job market shiftsJuly 2025 Rallies & Detailed Earnings Play Strategies - Newser
Eyepoint Pharmaceuticals stock hits 52-week high at 15.0 USD - Investing.com
Eyepoint Pharmaceuticals stock hits 52-week high at 15.0 USD By Investing.com - Investing.com Nigeria
Will EyePoint Pharmaceuticals Inc. (PV3B) stock outperform energy sector in 2025CPI Data & Weekly Return Optimization Plans - Newser
How buyback programs support EyePoint Pharmaceuticals Inc. (PV3B) stockJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - Newser
Is EyePoint Pharmaceuticals Inc. (PV3B) stock positioned for secular growthWeekly Earnings Recap & Fast Entry Momentum Alerts - Newser
Can EyePoint Pharmaceuticals Inc. (PV3B) stock deliver strong annual returnsJuly 2025 Drop Watch & Weekly Watchlist for Consistent Profits - Newser
EyePoint Pharmaceuticals: Promising Outlook for Duravyu in Wet AMD Treatment and Strategic Growth Potential - TipRanks
EyePoint Pharmaceuticals Director Sells Shares - TradingView
XTX Topco Ltd Acquires 94,210 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
What drives EyePoint Pharmaceuticals Inc stock priceEvening Star Patterns & Exceptional Return Capital - earlytimes.in
Investors Appear Satisfied With EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Prospects As Shares Rocket 26% - 富途牛牛
EyePoint Pharmaceuticals (EYPT) Is Up 8.4% After Positive Phase 3 Safety Review for DURAVYU - Sahm
Officer/Dir Lurker Files To Sell 500 Of EyePoint Pharmaceuticals Inc [EYPT] - TradingView
What analysts say about EyePoint Pharmaceuticals Inc PV3B stockHigh Dividend Yield Stocks & Access Free Risk Analysis Before You Invest - earlytimes.in
Avoiding Lag: Real-Time Signals in (EYPT) Movement - news.stocktradersdaily.com
EyePoint Pharmaceuticals (EYPT): A Fresh Valuation Look Following Key DURAVYU Phase 3 Safety Review Completion - sahmcapital.com
Will EyePoint Pharmaceuticals Inc. stock see PE expansionJuly 2025 Patterns & Stepwise Entry and Exit Trade Signals - BỘ NỘI VỤ
Eyepoint Pharmaceuticals stock hits 52-week high at $14.94 By Investing.com - Investing.com Nigeria
Eyepoint Pharmaceuticals stock hits 52-week high at $14.94 - Investing.com
EyePoint receives second consecutive positive recommendation from DSMC - Modern Retina
Why Institutions Believe Infibeam Avenues Limited Is Undervalued TodayStock Watchlist Updates & Collaborate and Win Together - earlytimes.in
EyePoint Pharmaceuticals (EYPT) Clears Phase 3 Safety Hurdle for DURAVYU—Is a New Wet AMD Era Ahead? - sahmcapital.com
Can EyePoint Pharmaceuticals Inc. (PV3B) stock sustain double digit ROETrade Risk Report & Detailed Earnings Play Alerts - newser.com
EyePoint Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals stock maintains Buy rating at H.C. Wainwright - Investing.com
Will EyePoint Pharmaceuticals Inc. (PV3B) stock beat growth indexesExit Point & Daily Technical Forecast Reports - newser.com
Is EyePoint Pharmaceuticals Inc. (PV3B) stock trading at attractive multiplesEarnings Risk Summary & Smart Swing Trading Alerts - newser.com
Is EyePoint Pharmaceuticals Inc. stock attractive for passive investorsJuly 2025 Summary & Scalable Portfolio Growth Methods - newser.com
Why ETFs are accumulating EyePoint Pharmaceuticals Inc. (PV3B) stock2025 Biggest Moves & Free Reliable Trade Execution Plans - newser.com
What margin trends mean for EyePoint Pharmaceuticals Inc. stockForecast Cut & Daily Technical Forecast Reports - newser.com
Will EyePoint Pharmaceuticals Inc. (PV3B) stock hit Wall Street targetsQuarterly Earnings Summary & Daily Oversold Bounce Ideas - newser.com
EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review - Yahoo Finance
How EyePoint Pharmaceuticals Inc. stock performs in high volatility marketsGold Moves & Precise Entry and Exit Recommendations - newser.com
Is EyePoint Pharmaceuticals Inc. stock ready for breakout2025 Bull vs Bear & Real-Time Volume Analysis - newser.com
Eyepoint Pharmaceuticals secures positive Phase 3 wet AMD trial review - Traders Union
EyePoint Gets Positive Recommendation for Wet AMD Trials From Safety Committee - MarketScreener
EyePoint (EYPT) Receives Green Light to Proceed with Phase 3 DUR - GuruFocus
Eyepoint Pharmaceuticals Inc (EYPT) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
1.10%
大文字化:
|
ボリューム (24 時間):